Oral Prescription Opioids as a High-Risk Indicator for Hepatitis C Infection: Another Step Toward HCV Elimination
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Primary Care & Community Health
- Vol. 12
Abstract
The opioid epidemic across the U.S. poses an array of public health concerns, especially HCV transmission. HCV is now widely curable, yet incident rates are increasing due to the opioid epidemic. Despite the established trajectory from oral prescription opioids (OPOs) to opioid use disorder (OUD), OUD to injection drug use (IDU), and IDU to hepatitis C virus (HCV), OPOs are not a defined risk factor (RF) for HCV infection. The objective of this study was to observe rates of HCV testing and Ab reactivity (HCVAb+) in patients receiving OPOs to substantiate them as a RF, ultimately contributing to HCV elimination. Data from MedStar Health patients receiving OPOs from 1/2017 to 12/2018 were collected and analyzed using chi-squared or student t-tests and logistic regression for uni- or multi-variable analyses, respectively. Statistical significance was defined as P < .05; Epi Info and SAS v 9·4 were used for statistical analyses; IRB approval was received. There were 115 415 individuals prescribed OPOs over the study period. In this population, 8.6% (932) were HCVAb+ when tested and not previously diagnosed (10 900); 3.4% (3893) had an OUD diagnosis, 20.6% (803) of whom were HCV tested; 25.4% (361) of all HCVAb+ (1421) had an OUD diagnosis. OUD (ORadj 8.53 [7.22-10.07]) was an independent predictor of HCVAb+ in this population. (1) In a large population prescribed oral opioids, HCVAb+ was 8.6%, higher than our previously published data (2.5%) and the US rate (1.7%); (2) only 20% of patients diagnosed with OUD were tested; and (3) only 25% of HCVAb+ patients were classified with OUD; this suggests underreporting of OUD in this population. Primary Care and Community Health Recommendations: (1) Re-testing for HCV in patients taking OPOs; (2) increased HCV testing among OUD patients; and (3) improved surveillance and reporting of OUD.Keywords
Funding Information
- Gilead Sciences
This publication has 29 references indexed in Scilit:
- Relationship between Nonmedical Prescription-Opioid Use and Heroin UseNew England Journal of Medicine, 2016
- Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013JAMA, 2015
- Opioid Use Trajectories, Injection Drug Use, and Hepatitis C Virus Risk Among Young Adult Immigrants from the Former Soviet Union Living in New York CityJournal of Addictive Diseases, 2015
- Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York CityJournal of Substance Abuse Treatment, 2015
- The Role of Opioid Prescription in Incident Opioid Abuse and Dependence Among Individuals With Chronic Noncancer PainThe Clinical Journal of Pain, 2014
- Screening for Hepatitis C Virus Infection in Adults: A Systematic Review for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2013
- Economic model of a birth cohort screening program for hepatitis C virusHepatology, 2011
- A Comparison of Common Screening Methods for Predicting Aberrant Drug-Related Behavior among Patients Receiving Opioids for Chronic Pain ManagementPain Medicine, 2009
- Evaluation of Screening Criteria to Identify Persons With Hepatitis C Virus Infection Among Sexually Transmitted Disease Clinic ClientsSexually Transmitted Diseases, 2003
- Performance Characteristics and Results of A Large–Scale Screening Program for Viral Hepatitis and Risk Factors Associated With Exposure to Viral Hepatitis B and C: Results of the National Hepatitis Screening SurveyHepatology, 1996